Why Are Pliant Therapeutics Shares Rallying Today?

  • Pliant Therapeutics Inc's PLRX Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and secondary endpoints.
  • The data demonstrated that PLN-74809 was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile. 
  • A pooled analysis of PLN-74809 treated patients showed an 80% reduction in forced vital capacity (FVC) decline at 12 weeks versus placebo.
  • Related: Read Why Pliant Therapeutics Shares Are Soaring Today?
  • The 40 mg and 160 mg dose groups demonstrated 38% and 66% reductions in FVC decline relative to placebo, respectively. 
  • In the 80 mg treatment group, a +24.6 mL increase in FVC was observed relative to baseline.
  • PLN-74809 was well tolerated at all three doses tested and exhibited dose-proportional increases in plasma concentrations, consistent with prior studies.
  • Pliant has recently completed enrollment in the 320 mg cohort of the INTEGRIS-IPF Phase 2a trial. The 12-week interim data from the 320 mg cohort is anticipated in early 2023. 
  • Price Action: PLRX shares are up 59.46% at $14.16 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!